This phytocannabinoid, at concentration ranging from 8.2 ± 0.3 μM to 10.6 ± 1.8 μM, inhibits the breast cancer cell proliferation through various mechanisms: (1) Blocks of cell cycle at the G1/S phase via CB1 and at the G2/M phase via CB2 activation, (2) induction of apoptosis by activation of the transcription factor jun-D, and (3) inhibition of AKT and increase of ROS generation [74]. This evidence concerns the gene CNR2 and breast carcinoma.